Last updated: November 8, 2026
Flurandrenolide is a mature, topical corticosteroid with commercial value concentrated in differentiated delivery systems rather than new-molecule exclusivity. The strongest opportunities are prescription generics, branded or private-label specialty formulations, flurandrenolide-impregnated tape, preservative-sensitive products, and vehicles that improve cosmetic acceptability or drug release. The conventional cream, lotion, and ointment markets are likely price-competitive because the active ingredient is old and generic products are available.
What products contain flurandrenolide?
Flurandrenolide is a synthetic corticosteroid used for corticosteroid-responsive dermatoses. U.S. products have included Cordran cream, lotion, ointment, and tape, along with generic formulations.
| Product type |
Typical strength or load |
Primary formulation issue |
Commercial position |
| Cream |
0.05% |
Emulsion stability, preservative system, skin feel |
Generic and branded-generic opportunity |
| Lotion |
0.05% |
Spreadability, evaporation, low residue |
Opportunity for large-area or hair-bearing sites |
| Ointment |
0.05% |
Occlusivity, greasiness, stability |
Smaller but clinically differentiated segment |
| Medicated tape |
4 mcg/cm² |
Adhesion, drug release, wear time |
Higher differentiation and manufacturing barrier |
| Compounded topical preparations |
Variable |
Uniformity and stability |
Limited, pharmacy-dependent market |
The FDA labeling for Cordran identifies flurandrenolide as a topical corticosteroid for inflammatory and pruritic corticosteroid-responsive dermatoses. The tape product provides an occlusive delivery system that can increase local drug exposure and maintain contact with the affected area (DailyMed, n.d.-a; DailyMed, n.d.-b).
What excipients are strategically important in flurandrenolide products?
Excipient selection determines product identity, skin tolerability, release performance, manufacturability, and generic-development risk. For flurandrenolide, the vehicle is commercially important because the active ingredient is available from multiple suppliers and has limited composition-of-matter value.
Cream vehicles
A cream formulation typically requires:
- An oil phase containing emollients or hydrocarbons
- An aqueous phase
- Emulsifiers and co-emulsifiers
- Humectants
- Viscosity modifiers
- Preservatives
- pH-control agents
- Antioxidants where required
The key development target is a stable, non-greasy emulsion that delivers flurandrenolide consistently without excessive irritation. A conventional oil-in-water cream may offer better patient acceptability than an ointment, but it creates more demanding preservative and microbial-control requirements.
Potential commercial differentiation includes:
- Lower residue after application
- Reduced tack
- Faster rub-in
- Fragrance-free and dye-free composition
- Low-irritancy preservative systems
- Compatibility with sensitive or atopic skin
- Packaging that limits contamination during repeated use
Excipients should be selected with reference to FDA’s Inactive Ingredient Database, route-specific precedent, dermatological safety, and product-specific stability data. The formulation should avoid unnecessary excipient changes that could complicate a 505(j) sameness argument.
Lotion vehicles
Lotion products are useful for large body areas and hair-bearing skin. They can provide better spreadability than creams or ointments, but they may be more vulnerable to runoff, drying, and inadequate dose deposition.
A commercial lotion strategy may use:
- Volatile emollients for rapid dry-down
- Humectants to reduce post-application dryness
- Lightweight emulsifiers
- Suspending agents if the formulation is a suspension
- Low-residue rheology modifiers
- Preservatives compatible with the pH and packaging
The principal development risk is balancing cosmetic elegance with dose uniformity. A thin lotion that dries quickly may be preferred by patients but can produce variable application amounts if it spreads too readily or runs from the treatment area.
Ointment vehicles
Ointments generally provide stronger occlusion and can improve hydration of the stratum corneum. Petrolatum, mineral oil, waxes, and related hydrocarbons are common excipient classes for this dosage form.
The advantages are:
- High barrier effect
- Strong skin moisturization
- Low water activity
- Reduced preservative burden
- Long physical stability
The disadvantages are greasiness, staining of clothing, poor acceptability on large areas, and limited convenience. An ointment can remain commercially relevant where clinicians prioritize occlusion over cosmetic performance.
Medicated tape
Flurandrenolide tape is the most defensible differentiated delivery system. The product combines a pressure-sensitive adhesive, backing material, release liner, and drug-containing matrix or coating. The formulation must control:
- Drug distribution across the tape
- Adhesive strength
- Cohesion
- Moisture resistance
- Skin compatibility
- Cutability and handling
- Drug release during wear
- Residue after removal
Tape creates a higher technical barrier than a standard cream because performance depends on both pharmaceutical composition and device-like physical properties. A competitor must establish consistent drug loading, adhesion, release, and wear performance at commercial scale.
What generic-development pathway applies to flurandrenolide?
A conventional cream, lotion, or ointment would generally be developed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence using the pathway applicable to the specific product.
Topical products can require more than a straightforward active-ingredient comparison. Relevant development issues include:
- Same active ingredient and strength
- Same dosage form
- Comparable inactive-ingredient function
- Comparative physicochemical characterization
- In vitro release testing
- Product quality and microstructure
- Stability
- Comparative clinical or dermatopharmacokinetic evidence where required
For a topical tape, the applicant must also address adhesion and delivery performance. A materially different adhesive or backing system could increase regulatory risk, even if the nominal active strength is the same.
What patents protect flurandrenolide products?
Flurandrenolide has no meaningful new-chemical-entity patent position in the U.S. Its commercial protection derives primarily from formulation know-how, manufacturing controls, trademarks, product presentation, and possible legacy patents relating to delivery systems.
| Protection category |
Likely relevance to flurandrenolide |
| Composition-of-matter patent |
Expired or commercially irrelevant because the active ingredient is longstanding |
| Standard cream or lotion formulation |
Limited protection; generic substitution is likely |
| Medicated tape construction |
More relevant because adhesive, backing, and release properties can be difficult to replicate |
| Method-of-use patent |
Limited practical value for established topical corticosteroid indications |
| Manufacturing process |
Potentially valuable as trade secret, especially for tape coating and drug uniformity |
| Trademark and trade dress |
Relevant to branded Cordran products but not a barrier to ANDA entry |
The FDA Orange Book is the primary source for current listed patents and exclusivity associated with approved products. Public FDA listings should be evaluated product by product because legacy topical products can have different listing histories (FDA, n.d.-a).
When does flurandrenolide lose exclusivity?
Flurandrenolide’s core regulatory exclusivity has long expired. The commercial question is therefore not loss of NCE exclusivity but the absence of meaningful remaining regulatory barriers.
| Exclusivity type |
Current commercial relevance |
| New chemical entity exclusivity |
Expired |
| Five-year new-drug exclusivity |
Not applicable to current generic competition |
| Three-year clinical-investigation exclusivity |
No apparent current role |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No apparent current role |
| Patent exclusivity |
Primarily legacy or product-specific, if any |
| ANDA 180-day exclusivity |
Possible only if an eligible first filer has an unresolved Paragraph IV position |
A Paragraph IV certification could arise only if a relevant listed patent remains in the Orange Book. Given the age of flurandrenolide products, the main generic risks are formulation and manufacturing complexity rather than basic active-ingredient patent protection.
What is the Orange Book status of flurandrenolide?
The Orange Book identifies approved drug products, therapeutic equivalence evaluations, patents, and exclusivity information. Flurandrenolide products should be reviewed by specific dosage form and strength because creams, lotions, ointments, and medicated tapes may have separate approval records and substitution ratings.
The practical regulatory assessment is:
- Conventional topical products are exposed to generic competition.
- Formulation differences can affect therapeutic-equivalence strategy.
- A tape product may have fewer direct competitors than a cream or lotion.
- The absence of a current patent barrier does not eliminate technical ANDA risk.
- Orange Book listings must be distinguished from patents that are expired, delisted, or no longer enforceable.
What formulation patents and manufacturing IP could create value?
The most valuable protectable assets would likely involve delivery and process performance rather than flurandrenolide itself.
Potential formulation claims
A company could seek protection for:
- A specific adhesive matrix that maintains therapeutic release
- A defined flurandrenolide concentration gradient
- A low-irritancy tape composition
- A water-resistant formulation with controlled release
- A preservative-free or low-preservative emulsion
- A formulation with defined particle-size distribution
- A vehicle that improves deposition without increasing systemic exposure
Patentability would depend on novelty, non-obviousness, written description, and demonstrated performance. Routine substitution of known dermatological excipients would face a higher obviousness risk.
Process and trade-secret assets
Manufacturing know-how may include:
- Homogenization order and shear conditions
- Temperature control during active incorporation
- Tape coating thickness
- Solvent removal
- Adhesive curing
- Roll-to-roll production parameters
- Content-uniformity controls
- Packaging and moisture-barrier selection
These controls can support commercial differentiation even where patent protection is weak. Trade-secret protection is strongest when process parameters are difficult to reverse-engineer from the finished product.
Which companies are challenging the flurandrenolide market?
The market is likely divided among legacy branded-product owners, generic dermatology manufacturers, contract manufacturers, and specialty pharmacies. Publicly available product listings identify approved manufacturers and labelers, but they do not reliably disclose market share or active commercial promotion.
The competitive field is most likely to include:
- Generic topical pharmaceutical companies selling flurandrenolide cream, lotion, or ointment.
- Specialty dermatology companies with branded-generic portfolios.
- Contract development and manufacturing organizations capable of semisolid production.
- Manufacturers with transdermal or medicated-tape capabilities.
- Compounding pharmacies serving patients when commercial products are unavailable.
A competitor with established semisolid manufacturing can enter creams and lotions relatively efficiently. Tape is less accessible because it requires specialized coating, adhesive, packaging, and performance testing.
What commercial opportunities exist for flurandrenolide?
1. Branded-generic cream
A branded-generic cream could compete through improved tolerability, low-residue performance, packaging, and payer contracting. The opportunity is constrained by therapeutic substitution and the availability of lower-cost generics.
2. Premium lotion
A lotion with better spreadability and cosmetic acceptability could target large-area use and hair-bearing sites. The main commercial hurdle is proving that the product offers enough practical benefit to justify a premium.
3. Flurandrenolide tape
Tape is the clearest niche opportunity. It may support higher pricing because the delivery system is differentiated and direct substitutes are fewer. The market remains limited by the specific clinical situations in which occlusion and localized delivery are appropriate.
4. Specialty dermatology licensing
Licensing opportunities could involve:
- An established flurandrenolide product with manufacturing capacity
- A tape platform
- A proprietary low-irritancy vehicle
- A regional commercialization agreement
- A private-label arrangement with a dermatology company
No major recent licensing transaction or settlement agreement is established in the cited public FDA and labeling sources. Deal economics would depend on net price, prescription volume, manufacturing yield, and payer coverage.
What revenue exposure and generic launch risks exist?
Public FDA and labeling sources do not provide reliable product-level revenue figures for flurandrenolide. Revenue exposure should therefore be assessed through prescription volume, reimbursement, channel concentration, and product mix rather than assumed sales estimates.
| Product |
Generic launch risk |
Margin outlook |
Main barrier |
| Cream |
High |
Low to moderate |
Price competition |
| Lotion |
Moderate to high |
Moderate |
Vehicle performance and substitution |
| Ointment |
Moderate |
Moderate |
Smaller demand base |
| Tape |
Lower direct competition |
Higher potential |
Adhesive and scale-up complexity |
A generic launch could produce rapid price erosion in standard semisolids. Tape may preserve pricing longer if only a small number of manufacturers can meet adhesion, release, and content-uniformity requirements.
How does flurandrenolide compare with competing topical corticosteroids?
Flurandrenolide competes with other topical corticosteroids, including hydrocortisone, triamcinolone acetonide, fluocinolone acetonide, betamethasone products, and other medium- or high-potency agents. Prescribers consider potency, dosage form, site of application, disease severity, tolerability, and cost.
| Competitive factor |
Flurandrenolide position |
| Active ingredient maturity |
Very mature |
| Patent protection |
Weak |
| Formulation differentiation |
Strongest in medicated tape |
| Generic availability |
Established |
| Payer leverage |
Generally unfavorable for standard forms |
| Manufacturing barrier |
Moderate for semisolids; higher for tape |
| Expansion potential |
Niche dermatology rather than broad-market growth |
Key Takeaways
- Flurandrenolide is a mature topical corticosteroid with limited value from active-ingredient exclusivity.
- Standard cream, lotion, and ointment products face substantial generic and price competition.
- The strongest commercial opportunity is a differentiated medicated tape or cosmetically superior topical vehicle.
- Excipient strategy should prioritize release, tolerability, stability, preservation, and patient adherence.
- Manufacturing know-how may be more valuable than broad formulation patent claims.
- A 505(j) pathway is the likely route for conventional generic products.
- Paragraph IV and Orange Book risks appear secondary to formulation, equivalence, and manufacturing execution.
- Public sources do not establish reliable current revenue figures or a major active licensing or settlement program for flurandrenolide.
FAQs
Is flurandrenolide still commercially relevant?
Yes. Its relevance is concentrated in topical dermatology niches, especially differentiated dosage forms such as medicated tape and patient-friendly vehicles.
Can flurandrenolide be reformulated without a new clinical trial?
A reformulated product may qualify for an abbreviated pathway if it meets applicable FDA requirements, but the evidence burden depends on the dosage form, formulation differences, and bioequivalence strategy.
Does flurandrenolide tape have stronger commercial potential than flurandrenolide cream?
Yes. Tape has greater technical differentiation and fewer direct competitors, although its total addressable market is smaller.
Are flurandrenolide excipients patentable?
Excipients themselves are generally known, but a novel combination, defined composition, delivery performance, or manufacturing process may support patent claims if statutory patentability requirements are met.
Is biosimilar competition relevant to flurandrenolide?
No. Flurandrenolide is a small-molecule topical drug, so competition proceeds through generic-drug pathways rather than biosimilar approval.
References
DailyMed. (n.d.-a). Cordran- flurandrenolide cream. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
DailyMed. (n.d.-b). Cordran- flurandrenolide tape. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.-b). Inactive ingredient database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-database-download
U.S. Food and Drug Administration. (n.d.-c). Generic drug user fee amendments: Product-specific guidances. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs ━
